Zelnorm lawsuits are now being reviewed
Zelnorm (generic tegaserod maleate) has been linked to an increased risk of heart attacks, strokes and other potentially life-threatening injuries. Last week the FDA requested that the Novartis Pharmaceutical Corporation halt sales of the drug for treatment of irritable bowel syndrome since the dangers associated with the medication outweigh the limited benefits provided by the drug. The lawyers at Saiontz, Kirk & Miles, P.A. are investigating lawsuits against the manufacturer for failing to properly warn of these Zelnorm side effects.
>>INFORMATION: Zelnorm lawsuits
The FDA identified the problems with Zelnorm after reviewing previous data collected from clinical trials. Novartis has acknowledged that the analysis identified an imbalance which was statistically significant in the number of heart attacks, strokes and occurrences of angina for individuals who took Zelnorm.
Experts have questioned why this data was not reviewed sooner. If earlier warnings had been issued it is possible that thousands of serious and potentially fatal injuries could have been prevented. When Zelnorm was approved in 2002, a small imbalance of angina pectoris was identified, but the makers minimized the risk. The recent re-review of the entire clinical database by independent experts has demonstrated that that the imbalance is statistically significant, and the product has been withdrawn from the market.
ZELNORM LAWYERS
The drug recall lawyers at Saiontz, Kirk & Miles, P.A. represent individuals injured by dangerous drugs and defective medical products nationwide. Zelnorm lawsuits are being reviewed to obtain compensation for those injured by this drug. Request a free claim evaluation.
